Alex Panaccione1, Yi Zhang1, Yanfang Mi1, Yoshitsugu Mitani2, Guo Yan3, Manju L Prasad4, W Hayes McDonald5, Adel K El-Naggar6, Wendell G Yarbrough7, Sergey V Ivanov8. 1. Section of Otolaryngology, Department of Surgery, Yale School of Medicine, 789 Howard Avenue, New Haven, CT 06519, USA. 2. Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. 3. Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. 4. Department of Pathology, Yale School of Medicine, New Haven, CT, USA. 5. Proteomics Laboratory, Mass Spectrometry Research Center, Nashville, TN 37232, USA; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA. 6. Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. 7. Section of Otolaryngology, Department of Surgery, Yale School of Medicine, 789 Howard Avenue, New Haven, CT 06519, USA; H&N Disease Center, Smilow Cancer Hospital, New Haven, CT, USA; Molecular Virology Program, Yale Cancer Center, New Haven, CT, USA. 8. Section of Otolaryngology, Department of Surgery, Yale School of Medicine, 789 Howard Avenue, New Haven, CT 06519, USA. Electronic address: sergey.ivanov@yale.edu.
Abstract
BACKGROUND: Mucinous adenocarcinoma of the salivary gland (MAC) is a lethal cancer with unknown molecular etiology and a high propensity to lymph node metastasis. Mostly due to its orphan status, MAC remains one of the least explored cancers that lacks cell lines and mouse models that could help translational and pre-clinical studies. Surgery with or without radiation remains the only treatment modality but poor overall survival (10-year, 44%) underscores the urgent need for mechanism-based therapies. METHODS: We developed the first patient-derived xenograft (PDX) model for pre-clinical MAC studies and a cell line that produces aggressively growing tumors after subcutaneous injection into nude mice. We performed cytogenetic, exome, and proteomic profiling of MAC to identify driving mutations, therapeutic targets, and pathways involved in aggressive cancers based on TCGA database mining and GEO analysis. RESULTS: We identified in MAC KRAS (G13D) and TP53 (R213X) mutations that have been previously reported as drivers in a variety of highly aggressive cancers. Somatic mutations were also found in KDM6A, KMT2D, and other genes frequently mutated in colorectal and other cancers: FAT1, NBEA, RELN, RLP1B, and ZFHX3. Proteomic analysis of MAC implied epigenetic up-regulation of a genetic program involved in proliferation and cancer stem cell maintenance. CONCLUSION: Genomic and proteomic analyses provided the first insight into potential molecular drivers of MAC metastases pointing at common mechanisms of CSC propagation in aggressive cancers. The in vitro/in vivo models that we created should aid in the development and validation of new treatment strategies against MAC.
BACKGROUND:Mucinous adenocarcinoma of the salivary gland (MAC) is a lethal cancer with unknown molecular etiology and a high propensity to lymph node metastasis. Mostly due to its orphan status, MAC remains one of the least explored cancers that lacks cell lines and mouse models that could help translational and pre-clinical studies. Surgery with or without radiation remains the only treatment modality but poor overall survival (10-year, 44%) underscores the urgent need for mechanism-based therapies. METHODS: We developed the first patient-derived xenograft (PDX) model for pre-clinical MAC studies and a cell line that produces aggressively growing tumors after subcutaneous injection into nude mice. We performed cytogenetic, exome, and proteomic profiling of MAC to identify driving mutations, therapeutic targets, and pathways involved in aggressive cancers based on TCGA database mining and GEO analysis. RESULTS: We identified in MAC KRAS (G13D) and TP53 (R213X) mutations that have been previously reported as drivers in a variety of highly aggressive cancers. Somatic mutations were also found in KDM6A, KMT2D, and other genes frequently mutated in colorectal and other cancers: FAT1, NBEA, RELN, RLP1B, and ZFHX3. Proteomic analysis of MAC implied epigenetic up-regulation of a genetic program involved in proliferation and cancer stem cell maintenance. CONCLUSION: Genomic and proteomic analyses provided the first insight into potential molecular drivers of MAC metastases pointing at common mechanisms of CSC propagation in aggressive cancers. The in vitro/in vivo models that we created should aid in the development and validation of new treatment strategies against MAC.
Authors: Michael J MacCoss; W Hayes McDonald; Anita Saraf; Rovshan Sadygov; Judy M Clark; Joseph J Tasto; Kathleen L Gould; Dirk Wolters; Michael Washburn; Avery Weiss; John I Clark; John R Yates Journal: Proc Natl Acad Sci U S A Date: 2002-06-11 Impact factor: 11.205
Authors: Larisa M Lehmer; Bruce D Ragsdale; Richard I Crawford; Roman Bukachevsky; Lauren A Hannah Journal: J Cutan Pathol Date: 2012-04-24 Impact factor: 1.587
Authors: Anna V Roschke; Oleg K Glebov; Samir Lababidi; Kristen S Gehlhaus; John N Weinstein; Ilan R Kirsch Journal: Neoplasia Date: 2008-11 Impact factor: 5.715
Authors: Michael L Nickerson; Garrett M Dancik; Kate M Im; Michael G Edwards; Sevilay Turan; Joseph Brown; Christina Ruiz-Rodriguez; Charles Owens; James C Costello; Guangwu Guo; Shirley X Tsang; Yingrui Li; Quan Zhou; Zhiming Cai; Lee E Moore; M Scott Lucia; Michael Dean; Dan Theodorescu Journal: Clin Cancer Res Date: 2014-09-15 Impact factor: 12.531
Authors: Theodoros Kantidakis; Marco Saponaro; Richard Mitter; Stuart Horswell; Andrea Kranz; Stefan Boeing; Ozan Aygün; Gavin P Kelly; Nik Matthews; Aengus Stewart; A Francis Stewart; Jesper Q Svejstrup Journal: Genes Dev Date: 2016-02-15 Impact factor: 11.361
Authors: Yoshitsugu Mitani; Sue-Hwa Lin; Kristen B Pytynia; Renata Ferrarotto; Adel K El-Naggar Journal: Clin Cancer Res Date: 2019-11-26 Impact factor: 12.531
Authors: Pierre Saintigny; Yoshitsugu Mitani; Kristen B Pytynia; Renata Ferrarotto; Dianna B Roberts; Randal S Weber; Merrill S Kies; Sankar N Maity; Sue-Hwa Lin; Adel K El-Naggar Journal: Cancer Date: 2018-10-05 Impact factor: 6.860
Authors: Benjamin R Nixon; Sara C Sebag; Michael S Glennon; Eric J Hall; Emily S Kounlavong; Michael L Freeman; Jason R Becker Journal: FASEB J Date: 2018-08-14 Impact factor: 5.191